Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship

Journal of Cardiology

Volumn 69, Issue 5, 2017, Pages 699-705

  Goudis, Christos A ^a  

^a General District Hospital of Serres   (Greece)

Author keywords

Atrial fibrillation; Chronic obstructive pulmonary disease; Pathophysiological mechanisms; Prognosis; Treatment

Indexed keywords

ADENOSINE; AMINOPHYLLINE; AMIODARONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIGOXIN; DILTIAZEM; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROPAFENONE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VERAPAMIL; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOCORTICOID;

ARRHYTHMOGENESIS; ATRIAL FIBRILLATION; CATHETER ABLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPOLARIZATION; DIASTOLIC DYSFUNCTION; ELECTROPHYSIOLOGY; ERYTHROCYTE SEDIMENTATION RATE; HEART REPOLARIZATION; HUMAN; HYPERCAPNIA; HYPOXEMIA; HYPOXIA; INFLAMMATION; MORTALITY; OXIDATIVE STRESS; PULMONARY HYPERTENSION; QUALITY OF LIFE ASSESSMENT; REVIEW; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; HEART PACING; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; GLUCOCORTICOIDS; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINERGIC P1 RECEPTOR ANTAGONISTS;

EID: 85011881665     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.12.013     Document Type: Review

References (94)

1. [1] Vestbo, J., Hurd, S.S., Agustí, A.G., Jones, P.W., Vogelmeier, C., Anzueto, A., Barnes, P.J., Fabbri, L.M., Martinez, F.J., Nishimura, M., Stockley, R.A., Sin, D.D., Rodriguez-Roisin, R., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187 (2013), 347–365.
2. [2] Adeloye, D., Chua, S., Lee, C., Basquill, C., Papana, A., Theodoratou, E., Nair, H., Gasevic, D., Sridhar, D., Campbell, H., Chan, K.Y., Sheikh, A., Rudan, I., Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015, 020415.
3. [3] Stewart, S., Hart, C.L., Hole, D.J., McMurray, J.J., A population-based study of the long term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113 (2002), 359–364.
4. [4] Beyerbach, D.M., Zipes, D.P., Mortality as an endpoint in atrial fibrillation. Heart Rhythm 1 (2004), 8–18.
5. [5] Buch, P., Friberg, J., Scharling, H., Lange, P., Prescott, E., Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 21 (2003), 1012–1016.
6. [6] Sidney, S., Sorel, M., Quesenberry, C.P. Jr., DeLuise, C., Lanes, S., Eisner, M.D., COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 128 (2005), 2068–2075.
7. [7] Mapel, D.W., Dedrick, D., Davis, K., Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991–1999. COPD 2 (2005), 35–41.
8. [8] Shibata, Y., Watanabe, T., Osaka, D., Abe, S., Inoue, S., Tokairin, Y., Igarashi, A., Yamauchi, K., Kimura, T., Kishi, H., Aida, Y., Nunomiya, K., Nemoto, T., Sato, M., Konta, T., et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 8 (2011), 514–522.
9. [9] Li, J., Agarwal, S.K., Alonso, A., Blecker, S., Chamberlain, A.M., London, S.J., Loehr, L.R., McNeill, A.M., Poole, C., Soliman, E.Z., Heiss, G., Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 129 (2014), 971–980.
10. [10] Johnson, L.S., Juhlin, T., Engström, G., Nilsson, P.M., Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace 16 (2014), 182–188.
11. [11] Chahal, H., Heckbert, S.R., Barr, R.G., Bluemke, D.A., Jain, A., Habibi, M., Alonso, A., Kronmal, R., Jacobs, D.R. Jr., Lima, J.A., Watson, K.E., Liu, K., Smith, L.J., Greenland, P., Ability of reduced lung function to predict development of atrial fibrillation in persons aged 45 to 84 years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study). Am J Cardiol 115 (2015), 1700–1704.
12. [12] Konecny, T., Park, J.Y., Somers, K.R., Konecny, D., Orban, M., Soucek, F., Parker, K.O., Scanlon, P.D., Asirvatham, S.J., Brady, P.A., Rihal, C.S., Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 114 (2014), 272–277.
13. [13] Geçmen, Ç., Babür Güler, G., Erdoğan, E., Hatipoğlu, S., Güler, E., Yılmaz, F., Unkun, T., Cap, M., Bengi Bakal, R., Bayram, T., Deniz Acar, R., Candan, Ö., Özdemir, N., SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery. Anatol J Cardiol 16 (2016), 655–661.
14. [14] Cerit, L., Duygu, H., Gulsen, K., Kemal, H.S., Ozcem, B., Balcioglu, O., Gunsel, A., Tosun, O., Emren, V., Is SYNTAX score predictive of atrial fibrillation after on-pump coronary artery bypass graft surgery?. Korean Circ J 46 (2016), 798–803.
15. [15] Mita, N., Kuroda, M., Miyoshi, S., Saito, S., Association of preoperative right and left ventricular diastolic dysfunction with postoperative atrial fibrillation in patients undergoing lung surgery: a prospective observational study. J Cardiothorac Vasc Anesth, 2016 [Epub ahead of print].
16. [16] Terzano, C., Romani, S., Conti, V., Paone, G., Oriolo, F., Vitarelli, A., Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 18 (2014), 2908–2917.
17. [17] Krause, P.C., Inoue, H., Zipes, D.P., Electrophysiologic alterations produced by hypoxia in the canine heart. Am Heart J 117 (1989), 550–561.
18. [18] Stevenson, I.H., Roberts-Thomson, K.C., Kistler, P.M., Edwards, G.A., Spence, S., Sanders, P., Kalman, J.M., Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm 7 (2010), 1263–1270.
19. [19] Lammers, W.J., Kirchhof, C., Bonke, F.I., Allessie, M.A., Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol 262 (1992), H47–H55.
20. [20] Ogi, H., Nakano, Y., Niida, S., Dote, K., Hirai, Y., Suenari, K., Tonouchi, Y., Oda, N., Makita, Y., Ueda, S., Kajihara, K., Imai, K., Sueda, T., Chayama, K., Kihara, Y., Is structural remodeling of fibrillated atria the consequence of tissue hypoxia?. Circ J 74 (2010), 1815–1821.
21. [21] Xu, Y., Sharma, D., Du, F., Liu, Y., The role of Toll-like receptor 2 and hypoxia-induced transcription factor-1alpha in the atrial structural remodeling of non-valvular atrial fibrillation. Int J Cardiol 168 (2013), 2940–2941.
22. [22] Su, F., Zhang, W., Chen, Y., Ma, L., Zhang, H., Wang, F., Significance of hypoxia-inducible factor-1α expression with atrial fibrosis in rats induced with isoproterenol. Exp Ther Med 8 (2014), 1677–1682.
23. [23] Stewart, A.G., Waterhouse, J.C., Howard, P., The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 89 (1995), 79–84.
24. [24] Sievi, N.A., Clarenbach, C.F., Camen, G., Rossi, V.A., van Gestel, A.J., Kohler, M., High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med, 14, 2014, 55.
25. [25] Mandyam, M.C., Soliman, E.Z., Alonso, A., Dewland, T.A., Heckbert, S.R., Vittinghoff, E., Cummings, S.R., Ellinor, P.T., Chaitman, B.R., Stocke, K., Applegate, W.B., Arking, D.E., Butler, J., Loehr, L.R., Magnani, J.W., et al. The QT interval and risk of incident atrial fibrillation. Heart Rhythm 10 (2013), 1562–1568.
26. [26] Nguyen, K.T., Gladstone, R.A., Dukes, J.W., Nazer, B., Vittinghoff, E., Badhwar, N., Vedantham, V., Gerstenfeld, E.P., Lee, B.K., Lee, R.J., Tseng, Z.H., Olgin, J.E., Scheinman, M.M., Marcus, G.M., The, Q.T., interval as a noninvasive marker of atrial refractoriness. Pacing Clin Electrophysiol, 2016 [Epub ahead of print].
27. [27] Caglar, I.M., Dasli, T., Turhan Caglar, F.N., Teber, M.K., Ugurlucan, M., Ozmen, G., Evaluation of atrial conduction features with tissue Doppler imaging in patients with chronic obstructive pulmonary disease. Clin Res Cardiol 101 (2012), 599–606.
28. [28] Acar, G., Kahraman, H., Akkoyun, M., Kilinc, M., Zencir, C., Yusufoglu, E., Dirnak, I., Sahin, H., Olmez, S., Akcay, A., Ardic, I., Evaluation of atrial electromechanical delay and its relationship to inflammation and oxidative stress in patients with chronic obstructive pulmonary disease. Echocardiography 31 (2014), 579–585.
29. [29] Tükek, T., Yildiz, P., Akkaya, V., Karan, M.A., Atilgan, D., Yilmaz, V., Korkut, F., Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 7 (2002), 222–227.
30. [30] Bhatt, S.P., Nanda, S., Kintzer, J.S., Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 106 (2012), 1134–1138.
31. [31] Hayashi, H., Miyamoto, A., Kawaguchi, T., Naiki, N., Xue, J.Q., Matsumoto, T., Murakami, Y., Horie, M., P-pulmonale and the development of atrial fibrillation. Circ J 78 (2014), 329–337.
32. [32] Buzea, C.A., Dan, A.R., Delcea, C., Balea, M.I., Gologanu, D., Dobranici, M., Popescu, R.A., Dan, G.A., P wave signal-averaged electrocardiography in patients with chronic obstructive pulmonary disease. Rom J Intern Med 53 (2015), 315–320.
33. [33] Baum, C., Ojeda, F.M., Wild, P.S., Rzayeva, N., Zeller, T., Sinning, C.R., Pfeiffer, N., Beutel, M., Blettner, M., Lackner, K.J., Blankenberg, S., Münzel, T., Rabe, K.F., Schnabel, R.B., Gutenberg Health Study investigators. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol 218 (2016), 298–304.
34. [34] Eweda, I., Hamada, G., Concordance between Doppler and pulsed-wave Doppler tissue imaging in estimation of the degree of left ventricular dysfunction and correlating it to the degree of chronic obstructive pulmonary disease. J Saudi Heart Assoc 28 (2016), 15–21.
35. [35] Caram, L.M., Ferrari, R., Naves, C.R., Tanni, S.E., Coelho, L.S., Zanati, S.G., Minicucci, M.F., Godoy, I., Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease. Clinics 68 (2013), 772–776.
36. [36] Agoston-Coldea, L., Petrovai, D., Mihalcea, I., Revnic, R., Mocan, T., Lupu, S., Right atrium volume index in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease. Acta Cardiol Sin 31 (2015), 325–336.
37. [37] Roh, S.Y., Choi, J.I., Lee, J.Y., Kwak, J.J., Park, J.S., Kim, J.B., Lim, H.E., Kim, Y.H., Catheter ablation of atrial fibrillation in patients with chronic lung disease. Circ Arrhythm Electrophysiol 4 (2011), 815–822.
38. [38] Kirkham, P.A., Barnes, P.J., Oxidative stress in COPD. Chest 144 (2013), 266–273.
39. [39] Gan, W.Q., Man, S.F., Senthilselvan, A., Sin, D.D., Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004), 574–580.
40. [40] Huang, C.X., Liu, Y., Xia, W.F., Tang, Y.H., Huang, H., Oxidative stress: a possible pathogenesis of atrial fibrillation. Med Hypotheses 72 (2009), 466–467.
41. [41] Harada, M., Van Wagoner, D.R., Nattel, S., Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 79 (2015), 495–502.
42. [42] Volchkova, E.A., Nikitin, A.G., Zotova, I.V., Zateyshchikova, A.A., Shavrin, I.V., Safaryan, V.I., Nosikov, V.V., Zateyshchikov, D.A., Atrial fibrillation in patients with chronic obstructive pulmonary disease is associated with polymorphism of interleukin 6 gene. Kardiologiia 55 (2015), 31–36.
43. [43] Wilchesky, M., Ernst, P., Brophy, J.M., Platt, R.W., Suissa, S., Bronchodilator use and the risk of arrhythmia in COPD: Part 2: reassessment in the larger Quebec cohort. Chest 142 (2012), 305–311.
44. [44] Cazzola, M., Imperatore, F., Salzillo, A., Di Perna, F., Calderaro, F., Imperatore, A., Matera, M.G., Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114 (1998), 411–415.
45. [45] Salpeter, S.R., Ormiston, T.M., Salpeter, E.E., Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 (2004), 2309–2321.
46. [46] Kallergis, E.M., Manios, E.G., Kanoupakis, E.M., Schiza, S.E., Mavrakis, H.E., Klapsinos, N.K., Vardas, P.E., Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 127 (2005), 2057–2063.
47. [47] Singh, S., Loke, Y.K., Enright, P., Furberg, C.D., Pro-arrhythmic and proischaemic effects of inhaled anticholinergic me-dications. Thorax 68 (2013), 114–116.
48. [48] Anthonisen, N.R., Connett, J.E., Enright, P.L., Manfreda, J., Lung Health Study Research Group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 166 (2002), 333–339.
49. [49] Ogale, S.S., Lee, T.A., Au, D.H., Boudreau, D.M., Sullivan, S.D., Cardiovascular events associated with ipratropium bromide in COPD. Chest 137 (2010), 13–19.
50. [50] Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008), 1543–1554.
51. [51] Kesten, S., Jara, M., Wentworth, C., Lanes, S., Pooled clinical trial analysis of tiotropium safety. Chest 130 (2006), 1695–1703.
52. [52] Hohlfeld, J.M., Furtwaengler, A., Könen-Bergmann, M., Wallenstein, G., Walter, B., Bateman, E.D., Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract 69 (2015), 72–80.
53. [53] Wedzicha, J.A., Dahl, R., Buhl, R., Schubert-Tennigkeit, A., Chen, H., D'Andrea, P., Fogel, R., Banerji, D., Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 108 (2014), 1498–1507.
54. [54] Huerta, C., Lanes, S.F., García Rodríguez, L.A., Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 16 (2005), 360–366.
55. [55] Wood-Baker, R., Cochrane, B., Naughton, M.T., Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J 40 (2010), 94–101.
56. [56] Eiriksson, C.E. Jr., Writer, S.L., Vestal, R.E., Theophylline-induced alterations in cardiac electrophysiology in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 135 (1987), 322–326.
57. [57] Shukla, D., Chakraborty, S., Singh, S., Mishra, B., Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother 10 (2009), 2343–2356.
58. [58] Christiansen, C.F., Christensen, S., Mehnert, F., Cummings, S.R., Chapurlat, R.D., Sørensen, H.T., Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study. Arch Intern Med 169 (2009), 1677–1683.
59. [59] van der Hooft, C.S., Heeringa, J., Brusselle, G.G., Hofman, A., Witteman, J.C., Kingma, J.H., Sturkenboom, M.C., Stricker, B.H., Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166 (2006), 1016–1020.
60. [60] Grabicki, M., Parysek, H., Batura-Gabryel, H., Brodnicka, I., Comorbidities as an element of multidimensional prognostic assessment of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol 59:Suppl 6 (2008), 297–301.
61. [61] Kalaycıoğlu, E., Gökdeniz, T., Aykan AÇ, Hatem, E., Gürsoy, M.O., Toksoy, F., Dursun, I., Çelik, S., Evaluation of left ventricular function and its relationship with multidimensional grading system (BODE index) in patients with COPD. COPD 12 (2015), 568–574.
62. [62] Gökdeniz, T., Kalaycıoğlu, E., Boyacı, F., Aykan AÇ, Gürsoy, M.O., Hatem, E., Börekçi, A., Karabag, Y., Altun, S., The BODE index, a multidimensional grading system, reflects impairment of right ventricle functions in patients with chronic obstructive pulmonary disease: a speckle-tracking study. Respiration 88 (2014), 223–233.
63. [63] Steer, J., Gibson, J., Bourke, S.C., The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 67 (2012), 970–976.
64. [64] de Vos, C.B., Pisters, R., Nieuwlaat, R., Prins, M.H., Tieleman, R.G., Coelen, R.J., van den Heijkant, A.C., Allessie, M.A., Crijns, H.J., Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55 (2010), 725–731.
65. [65] Tischer, T.S., Schneider, R., Lauschke, J., Diedrich, D., Kundt, G., Bänsch, D., Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of patients with high HATCH score. Herz 40 (2015), 803–808.
66. [66] Chen, K., Bai, R., Deng, W., Gao, C., Zhang, J., Wang, X., Wang, S., Fu, H., Zhao, Y., Zhang, J., Dong, J., Ma, C., HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm 12 (2015), 1483–1489.
67. [67] Emren, V., Aldemir, M., Duygu, H., Kocabaş, U., Tecer, E., Cerit, L., Erdil, N., Usefulness of HATCH score as a predictor of atrial fibrillation after coronary artery bypass graft. Kardiol Pol, 2016 [Epub ahead of print].
68. [68] Emren, S.V., Kocabaş, U., Duygu, H., Levent, F., Şimşek EÇ, Yapan Emren, Z., Tülüce, S., The role of HATCH score in predicting the success rate of sinus rhythm following electrical cardioversion of atrial fibrillation. Kardiol Pol 74 (2016), 978–984.
69. [69] Kochhäuser, S., Dechering, D.G., Trought, K., Hache, P., Haig-Carter, T., Khaykin, Y., Wulffhart, Z., Pantano, A., Tsang, B., Eckardt, L., Verma, A., Predictors for progression of atrial fibrillation in patients awaiting atrial fibrillation ablation. Can J Cardiol 32 (2016), 1348–1354.
70. [70] Pisters, R., Nieuwlaat, R., Prins, M.H., Le Heuzey, J.Y., Maggioni, A.P., Camm, A.J., Crijns, H.J., Euro Heart Survey Investigators, Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 14 (2012), 666–674.
71. [71] Gu, J., Liu, X., Tan, H., Zhou, L., Jiang, W., Wang, Y., Liu, Y., Gu, J., Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol 24 (2013), 148–154.
72. [72] Nadeem, R., Sharieff, A., Tanna, S., Sidhu, H., Molnar, J., Nadeem, A., Potential augmentation of the risk of ischemic cerebrovascular accident by chronic obstructive pulmonary disease in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 24 (2015), 1893–1896.
73. [73] Proietti, M., Laroche, C., Drozd, M., Vijgen, J., Cozma, D.C., Drozdz, J., Maggioni, A.P., Boriani, G., Lip, G.Y., EORP-AF Investigators, Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Am Heart J 181 (2016), 83–91.
74. [74] Huang, B., Yang, Y., Zhu, J., Liang, Y., Zhang, H., Tian, L., Shao, X., Wang, J., Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc 15 (2014), 576–581.
75. [75] Pokorney, S.D., Piccini, J.P., Stevens, S.R., Patel, M.R., Pieper, K.S., Halperin, J.L., Breithardt, G., Singer, D.E., Hankey, G.J., Hacke, W., Becker, R.C., Berkowitz, S.D., Nessel, C.C., Mahaffey, K.W., Fox, K.A., et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc, 5, 2016, e002197.
76. [76] Durheim, M.T., Cyr, D.D., Lopes, R.D., Thomas, L.E., Tsuang, W.M., Gersh, B.J., Held, C., Wallentin, L., Granger, C.B., Palmer, S.M., Al-Khatib, S.M., Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. Int J Cardiol 202 (2016), 589–594.
77. [77] Atzema, C.L., Dorian, P., Fang, J., Tu, J.V., Lee, D.S., Chong, A.S., Austin, P.C., A Clinical decision instrument for 30-day death after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. Ann Emerg Med 66 (2015), 658–668 e6.
78. [78] Roversi, S., Fabbri, L.M., Sin, D.D., Hawkins, N.M., Agustí, A., Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med 194 (2016), 1319–1336.
79. [79] Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Crim, C., Willits, L.R., Yates, J.C., Vestbo, J., TORCH Investigators, Cardiovascular events in patients with COPD: TORCH study results. Thorax 65 (2010), 719–725.
80. [80] Wise, R.A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., Dusser, D., Joseph, E., Kattenbeck, S., Koenen-Bergmann, M., Pledger, G., Calverley, P., TIOSPIR Investigators, Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369 (2013), 1491–1501.
81. [81] Wilchesky, M., Ernst, P., Brophy, J.M., Platt, R.W., Suissa, S., Bronchodilator use and the risk of arrhythmia in COPD: Part 1: Saskatchewan cohort study. Chest 142 (2012), 298–304.
82. [82] Sessler, C.N., Cohen, M.D., Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 98 (1990), 672–678.
83. [83] Ohta, K., Fukuchi, Y., Grouse, L., Mizutani, R., Rabe, K.F., Rennard, S.I., Zhong, N.-S., A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 98 (2004), 1016–1024.
84. [84] Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A.S., Oldgren, J., Popescu, B.A., Schotten, U., et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J, 2016 pii:ehw210.
85. [85] Delle Karth, G., Geppert, A., Neunteufl, T., Priglinger, U., Haumer, M., Gschwandtner, M., Siostrzonek, P., Heinz, G., Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 29 (2001), 1149–1153.
86. [86] Goldman, S., Probst, P., Selzer, A., Cohn, K., Inefficacy of “therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 35 (1975), 651–655.
87. [87] Kuralay, E., Cingöz, F., Kiliç, S., Bolcal, C., Günay, C., Demirkiliç, U., Tatar, H., Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 25 (2004), 224–230.
88. [88] Neef, P.A., McDonald, C.F., Burrell, L.M., Irving, L.B., Johnson, D.F., Steinfort, D.P., Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease. Intern Med J 46 (2016), 1336–1340.
89. [89] Salpeter, S., Ormiston, T., Salpeter, E., Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev(4), 2005, CD003566.
90. [90] Ni, Y., Shi, G., Wan, H., Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 40 (2012), 2051–2065.
91. [91] Du, Q., Sun, Y., Ding, N., Lu, L., Chen, Y., Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLOS ONE, 9, 2014, e113048.
92. [92] January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C. Jr., Conti, J.B., Ellinor, P.T., Ezekowitz, M.D., Field, M.E., Murray, K.T., Sacco, R.L., Stevenson, W.G., Tchou, P.J., Tracy, C.M., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
93. [93] Kumar, N., Pison, L., La Meir, M., Maessen, J., Crijns, H.J., Hybrid approach to atrial fibrillation ablation using bipolar radiofrequency devices epicardially and cryoballoon endocardially. Interact Cardiovasc Thorac Surg 19 (2014), 590–594.
94. [94] Huang, B., Yang, Y., Radiofrequency catheter ablation of atrial fibrillation in patients with chronic obstructive pulmonary disease: opportunity and challenge: response to Dr. Kumar's comment. J Am Med Dir Assoc 16 (2015), 83–84.